69,986 Shares in NeoGenomics, Inc. (NASDAQ:NEO) Acquired by Semanteon Capital Management LP

Semanteon Capital Management LP bought a new position in shares of NeoGenomics, Inc. (NASDAQ:NEO) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 69,986 shares of the medical research company’s stock, valued at approximately $1,132,000.

Several other hedge funds also recently modified their holdings of the stock. Redwood Investments LLC bought a new stake in shares of NeoGenomics in the 4th quarter worth $2,399,000. SG Americas Securities LLC purchased a new stake in NeoGenomics during the third quarter valued at about $1,844,000. Aigen Investment Management LP bought a new stake in shares of NeoGenomics during the third quarter valued at about $163,000. Legato Capital Management LLC bought a new stake in shares of NeoGenomics during the fourth quarter valued at about $401,000. Finally, Illinois Municipal Retirement Fund bought a new stake in shares of NeoGenomics during the third quarter valued at about $960,000. Institutional investors own 98.50% of the company’s stock.

Insiders Place Their Bets

In other NeoGenomics news, General Counsel Alicia C. Olivo sold 2,587 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $14.96, for a total value of $38,701.52. Following the sale, the general counsel now owns 34,866 shares in the company, valued at $521,595.36. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 1.30% of the company’s stock.

NeoGenomics Trading Down 1.3 %

NASDAQ:NEO traded down $0.18 during midday trading on Thursday, hitting $13.85. 791,476 shares of the company traded hands, compared to its average volume of 893,511. The firm’s fifty day moving average is $15.04 and its 200-day moving average is $15.88. NeoGenomics, Inc. has a 12-month low of $11.03 and a 12-month high of $21.22. The firm has a market capitalization of $1.77 billion, a P/E ratio of -19.79 and a beta of 1.10. The company has a current ratio of 6.20, a quick ratio of 5.95 and a debt-to-equity ratio of 0.57.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Tuesday, February 20th. The medical research company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.05. NeoGenomics had a negative return on equity of 4.13% and a negative net margin of 14.87%. The company had revenue of $155.55 million for the quarter, compared to analyst estimates of $152.90 million. On average, sell-side analysts predict that NeoGenomics, Inc. will post -0.2 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on NEO. William Blair restated an “outperform” rating on shares of NeoGenomics in a research report on Wednesday, February 21st. Needham & Company LLC increased their price objective on NeoGenomics from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, February 21st. Piper Sandler raised their price target on NeoGenomics from $18.00 to $20.00 and gave the stock an “overweight” rating in a research note on Monday, February 26th. The Goldman Sachs Group raised their price objective on NeoGenomics from $17.00 to $19.00 and gave the company a “buy” rating in a research report on Thursday, February 22nd. Finally, BTIG Research lowered their price objective on NeoGenomics from $25.00 to $21.00 and set a “buy” rating for the company in a research report on Friday, December 29th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $19.50.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.